Academic Entrepreneurs, New Technologies, and Building Companies to Treat Rare Diseases:

A personal history

Professor Harvey Lodish
Whitehead Institute for Biomedical Research
Departments of Biology and Biological Engineering, Massachusetts Institute of Technology
Although I have helped start several successful biotechnology companies, at heart I am a cell and developmental biologist focused on understanding basic life processes

- 1979  Damon Biotech
- 1979  BioInformation Associates
- 1981  Genzyme
  Sold to Sanofi for $20.2 billion
- 1983  Arris (now Axys) Pharmaceuticals
- 1993  Millennium Pharmaceuticals
  Sold to Takeda for $9 billion
- 2005  Allozyne
- 2014  Rubius
- 2017  Tevard

From 2007 to 2016 I was the Founding Chair of the Scientific Advisory Board of the Massachusetts Life Sciences Center, the agency charged with oversight of the state’s 10-year $1 billion investment in the life sciences.

Since 2007 I have served on the Board of Trustees of Boston Children’s Hospital and as the Chair of the Board of Trustees Research Committee
Developing cures for many diseases requires intense collaborations:

Not for profit:
• Academic laboratories researching the underlying basic cellular and molecular biology
• Medical centers and research hospitals studying the disease or condition
• Government support of research and development
• Patient or disease based national or international organizations
• Philanthropic support of research and development

GOAL: One or more candidate drugs that work in cell cultures and/or experimental animals

For profit:
• Venture capital
• Patient or disease based organizations
• Small to medium sized biotech companies
• Multinational biopharmaceutical companies

GOAL: An FDA-approved drug that is available to all patients
Developing cures for most diseases requires intense collaborations and costs a considerable amount of money.
New types of therapeutics are entering clinical practice and form the basis of successful companies

• Small molecule drugs

• Proteins as therapeutics (~1980)
  - Monoclonal antibodies
  - Recombinant therapeutic proteins

• Cell therapies (~2010)
  - Replacement cells (e.g. pancreatic islets)
  - Engineered cells (e.g. red blood cells expressing therapeutic proteins; anti-cancer T cells)

• Nucleic acid therapies (~2010)

• Gene therapies (~2010)

• Gene editing (~2020?)
Policies of most U.S. research universities encourage faculty members to become entrepreneurs and start and build companies

• One day per week “Outside Professional Activity”
  – For-profit companies
  – Not-for-profit organizations
• Faculty can consult for and own stock in companies but cannot be an operating officer
• Clear conflict of interest rules
Many of my 16 faculty colleagues at the Whitehead Institute at M.I.T. have also founded publicly-traded biotechnology companies during the past 10 years:

- FoldRx; acquired by Pfizer (Susan Lindquist)
- Computational Biology Company; acquired by Agilent (Rick Young)
- Alnylam Pharmaceuticals (Dave Bartel)
- Verastem (Bob Weinberg, Piyush Gupta)
- Syros Pharmaceuticals (Rick Young)
- Fate Therapeutics (Rudolf Jaenisch)
- Ironwood Pharmaceuticals (Gerry Fink)
In aggregate rare diseases affect an estimated 25 to 30 million people in the United States

- Definition: Any disease or condition that affects fewer than 200,000 people in the United States
- There are more than 6,800 rare diseases
- Similar to the United States, Europe has approximately 30 million people living with rare diseases.
- It is estimated that 350 million people worldwide suffer from rare diseases

Parent Powered Innovation
www.parentpoweredinnovation.org
Some examples of rare diseases: Most have been identified in Caucasians

- Cystic Fibrosis
- Phenylketonuria (PKU)
- Muscular Dystrophy
- Tay-Sachs
- Gaucher Disease
- Beta Thalassemia
- Familial Hypercholesterolemia
- Progeria
- Tourette Syndrome
- Severe Combined Immune Deficiency (Bubble boy disease)
- Dravet’s Syndrome
- Kleefstra Syndrome
Most rare diseases are of genetic origin and appear early in life

• 80% of rare diseases are genetic in origin, and thus are present throughout a person’s life, even if symptoms do not immediately appear

• Approximately 50% of the people affected by rare diseases are children

Parent Powered Innovation
www.parentpoweredinnovation.org
Because of intermarriage, every ethnic group has its own constellation of rare genetic diseases.

Iceland:
Population 300,000; founded 1,100 years ago by between 8,000 and 20,000 people mainly from Scandinavia, Ireland and Scotland.

- Recessive frameshift mutation in \( MYL4 \) (myosin essential light chain) causing early-onset atrial fibrillation.
- Mutation in \( ABDB4 \) (Multidrug resistance protein 3) increasing risk of gallstones


Finland:

- Mutation in \( SLC26A2 \) (Sulfate transporter) causing recessive multiple epiphyseal dysplasia (EDM4/rMED)

J. Hästbacka et. al., Cell 78: 1073 – 1087 (1994)
Many rare diseases can be prevented by prenatal screening of members of at-risk ethnic groups.

- They test for common, incurable recessive diseases that present serious health issues or risk of fatality and for which there exists reliable testing methods with definitive carrier status results.
- They test for 16 diseases affecting Ashkenazic (Eastern European) Jews and 16 diseases common in Sephardic (Western European) Jews.
- Tay-Sachs and other genetic diseases have been virtually eliminated in these ethnic groups.
Most rare diseases currently lack appropriate treatment options

• According to the Kakkis EveryLife Foundation, 95% of rare diseases have not one single FDA - approved drug treatment

• Approximately 50% of rare diseases do not have a disease specific foundation supporting or researching the disease

• During the first 25 years of the U. S. Orphan Drug Act (passed in 1983), only 326 new drugs were approved by the FDA and brought to market for all rare diseases combined

• In general, large pharmaceutical companies are not pursuing new drugs for rare diseases, focusing instead on drugs for more common diseases such as diabetes, cancer, and cardiovascular disease.
• Genzyme: An enzyme replacement therapy for Gaucher Disease

• Rubius: A potential treatment for Phenylketonuria (PKU)

• Gene therapy treatments for rare diseases
• Genzyme: An enzyme replacement therapy for Gaucher Disease

• Rubius: A potential treatment for Phenylketonuria (PKU)

• Gene therapy treatments for rare diseases
Type I Gaucher Disease

- A lysosome storage disease
- Type I Gaucher is a progressive, debilitating and sometimes life-threatening disease.
- Symptoms can include: easy bleeding and bruising, fatigue, anemia, weak bones, bone and joint pain, and enlargement of the spleen or liver.
- Symptoms can appear at any age.
Gaucher Disease primarily affects macrophages

• Macrophage: from Greek μακρος (makros) = large, φαγειν (phagein) = to eat.

• Gaucher disease is the most common lysosomal storage disease.

• Autosomal recessive deficiency of the lysosomal enzyme β glucocerebrosidase (also called acid β glucosidase), essential for the degradation of the glycolipid glucocerebroside

• Enzyme deficiency causes accumulation of glucocerebrosides, particularly in macrophages in the spleen, liver, kidneys, lungs, brain, and bone marrow, and causes symptoms of the disease.
Enzyme replacement therapy for Type I Gaucher Disease

• Replacement enzyme is targeted to macrophages via the macrophage mannose receptor, internalized by receptor-mediated endocytosis, and delivered to lysosomes
Structure of asparagine-linked oligosaccharides attached to yeast cell surface proteins

GlcNAc = N Acetyl glucosamine

M = Mannose

Phagocytosis of yeast cells by macrophages and transfer of the endocytosed particles to lysosomes utilizes macrophage cell surface mannose receptors.
Enzymic formation of the modified mannose-terminal N-linked oligosaccharides on Cerezyme™ that target injected glucocerebrosidase protein to the macrophage mannose receptor, where it is internalized by endocytosis and transported to lysosomes.

1) Neuraminidase
2) β- Galactosidase
3) β- N-acetylglucosaminidase

• A personalized medicine for a rare disease
• A recombinant protein
• A protein targeted to a specific type of cell
• Based on engineering sugars attached to proteins
One of my seven grandchildren has Gaucher Disease, and is being treated with the Genzyme drug that his grandfather helped develop.
“The whole basis of why we do research came full circle for me, born of the cell biology we were studying in the early 80s. Of course I couldn’t know where this was heading in my own life, but the real power of the story is that it brings home the importance of basic science. That’s the key lesson.”
## Other Genzyme Recombinant Enzymes to Treat Rare Diseases

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fabrazyme® (agalsidase beta) Alpha-galactosidase</td>
<td>Fabry disease</td>
</tr>
<tr>
<td>Lumizyme® (alglucosidase alfa) Alpha-glucosidase</td>
<td>Pompe Disease Glycogen storage disease Type II</td>
</tr>
<tr>
<td>Aldurazyme® (laronidase) Glycosaminoglycan alpha-L-iduronohydrolase</td>
<td>Mucopolysaccharidosis I (MPS I)</td>
</tr>
</tbody>
</table>
• Genzyme: An enzyme replacement therapy for Gaucher Disease

• Rubius: A potential treatment for Phenylketonuria (PKU)

• Gene therapy treatments for rare diseases
A potential therapy for Phenylketonuria (PKU) and many other diseases based on genetically modified red blood cells
Phenylketonuria (PKU) is an autosomal recessive enzyme deficiency that can lead to irreversible brain damage

- Diagnosed at birth by a routine blood test
- An autosomal recessive genetic disease
- Deficiency of phenylalanine hydroxylase (PAH), an enzyme that breaks down phenylalanine
- If not properly managed, the increased levels of phenylalanine in the circulation cause nerve damage and intellectual disability.
- Mainstay of therapy is dietary restriction of phenylalanine through medical foods (cost: US $60,000 - $100,000/year)
Red cells are attractive microparticles for long-term introduction of therapeutics into the human body

- Blood transfusion is a widely used therapeutic
- 7 µm diameter flexible biconcave discs
- Long lifespan: 120 days in blood stream
- Large cell surface area and excellent biocompatibility
- Genes encoding foreign or chimeric proteins can be expressed in cultured erythroid progenitor cells
- Lack nucleus and mitochondria: no remnants of introduced DNAs
We developed a 21-day culture system for human bone marrow stem cells that generates millions of normal red blood cells.

Rubius’ solution

• Use recombinant DNA technology to introduce into blood stem cells the gene for a bacterial enzyme that degrades phenylalanine.

• Culture these blood stem cells under conditions where they divide ~16 times and differentiate into otherwise normal red blood cells that contain the phenylalanine-degrading enzyme.

• Transfuse these red cells into a PKU patient.
Human red blood cells containing the phenylalanine-degrading enzyme (RCT-Enz) degrade excess phenylalanine in human serum.
Mouse RBC-ENZs have a normal lifetime in transfused mice.
Rubius Therapeutics Inc. of Cambridge is set to announce Wednesday that it has raised $120 million — one of the largest biotech financing rounds this year — to develop a novel drug-making technology.
• Genzyme: An enzyme replacement therapy for Gaucher Disease

• Rubius: A potential treatment for Phenylketonuria (PKU)

• Potential gene therapy treatments for rare diseases
Strategy for ex vivo gene correction of monogenic blood cell and immune system diseases using hematopoietic stem cells

Advantages of gene therapy:
- No donor search
- No chance of Graft versus Host Disease (GVHD)
- Cross-correction with supra-physiological expression of transgene

Dr. Sung-Yun Pai
Severe Combined Immune Deficiency (SCID)
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency


ABSTRACT

BACKGROUND

In previous clinical trials involving children with X-linked severe combined immuno-deficiency (SCID-X1), a Moloney murine leukemia virus–based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1.

METHODS

We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc).

RESULTS

All patients received bone marrow–derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients.

CONCLUSIONS

This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown.

(Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01400019, NCT0175239, and NCT01129544.)
A boy with Severe Combined Immune Deficiency (SCID) from Argentina

A couple in Argentina had a boy with SCID, who died from a routine immunization.

They had another boy who was healthy, then A.C. was born June 2010 and diagnosed with SCID.

No bone marrow matches in family or in ~17 million donors in the worldwide bank.

His doctor reached out to Boston Children’s for help and he was enrolled on a trial of gene therapy for X-linked SCID (D.A. Williams Sponsor, S.-Y. Pai PI).
A normal life after gene therapy

5 months post

In school, thriving, no serious infections

2 years post

5 years post
Gene Therapy for X-linked SCID
Safe and effective

12 of 13 alive
(1 died of pre-existing infection)

10 of 12 have T cells from gene therapy
(2 had transplant and are well)

No serious infections

No leukemia

2-6 years of follow-up
A boy with Wiskott-Aldrich syndrome from Vietnam

Only child of a physician and bank manager in Vietnam

Diagnosed with Wiskott-Aldrich syndrome, symptoms of GI bleeding, fevers, eczema and vasculitis on the feet, preventing him from walking due to pain and swelling

Enrolled as the 5\textsuperscript{th} and last patient on trial of gene therapy for WAS (D.A. Williams, Sponsor, S.-Y. Pai, PI)
Successful stem cell gene therapy for Wiskott-Aldrich syndrome

No GI bleeding
Platelet transfusion independent
Was off the growth curve, now on
Vasculitis controlled
Took first steps 2 months post gene therapy
<table>
<thead>
<tr>
<th>Protocol Title</th>
<th>PI(s)</th>
<th>Sponsor</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene Transfer for SCID – X1 Using a Self Inactivating Gamma retroviral Vector</td>
<td>S. Pai</td>
<td>D. Williams</td>
<td><strong>Active and enrolling</strong>: 3 patients treated, conditioning added, 1 new patient consented plan for treatment 7/17</td>
</tr>
<tr>
<td>Pilot and feasibility of hematopoietic stem cell gene transfer for Wiskott – Aldrich Syndrome (WAS)</td>
<td>S. Pai</td>
<td>D. Williams</td>
<td><strong>Cohort complete</strong>: 5 patients treated, most recent patient treated, readying return home for follow up</td>
</tr>
<tr>
<td>A Phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD)</td>
<td>C. Duncan F. Eichler (MGH)</td>
<td>Bluebird Bio</td>
<td><strong>Active and enrolling</strong>: 12 patient treated at BCH, 20 total</td>
</tr>
<tr>
<td>Study of Lentiviral transduced CD 34+ cells for the treatment of X-linked Chronic Granulomatous Disease (CGD)</td>
<td>D. Williams P. Newburger S. Pai</td>
<td>UCLA – D. Kohn</td>
<td><strong>Active</strong>: 1st 3 patients treated, staggering enrollment ends this summer</td>
</tr>
<tr>
<td>A Phase I Trial of T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia</td>
<td>K. Curran S. Margossian L. Silverman</td>
<td>MSKCC</td>
<td><strong>Cohort completed</strong>: 7 subjects enrolled, 4 subject treated. Enrollment closed</td>
</tr>
<tr>
<td>A Phase I/II study of CaspaCide T Cells from an HLA - partially matched family donor after negative selection of TCR αβ+Tcell in pediatric patients affected by hematological disorders</td>
<td>S. Baumeister</td>
<td>Bellicum Pharmaceuticals</td>
<td><strong>Cohort complete</strong>: 2 patients treated, awaiting phase II –</td>
</tr>
<tr>
<td>Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients with Sickle Cell Disease</td>
<td>E. Esrick A. Biffi</td>
<td>A. Biffi Bluebird Bio</td>
<td><strong>Active and enrolling</strong>: 2 patients treated, 4 others scheduled for enrollment</td>
</tr>
<tr>
<td>Indication</td>
<td>PI(s)</td>
<td>Sponsor</td>
<td>Status</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>--------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector</td>
<td>S. Pai</td>
<td>D. Williams Orchard Therapeutics</td>
<td><strong>Regulatory stages:</strong> pending IND submission planned for June 2017, plan for study opening in Fall</td>
</tr>
<tr>
<td>Phase I/II Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease</td>
<td>E. Esrick, A. Biffi, M. Heeney, L. Lehmann</td>
<td>D. Williams Bluebird Bio (vector)</td>
<td><strong>Regulatory Stages:</strong> IND submission planned for June 2017, GMP vector production complete, certification in process IRB/IBC submission for June 2017</td>
</tr>
<tr>
<td>A Phase I trial of intra-ventricular hematopoietic stem cell transplantation for neurometabolic diseases</td>
<td>A. Biffi, C. Duncan, L. Goumnerova, S. Nikiforow</td>
<td>A. Biffi</td>
<td><strong>Regulatory Stages:</strong> Pre IND meeting held in February, preclinical work proceeding to support IND application</td>
</tr>
<tr>
<td>HSC gene therapy for Type IIIA Mucopolysaccharidosis</td>
<td>A. Biffi</td>
<td>Orchard Therapeutics</td>
<td><strong>Pre-clinical development phase:</strong> received Orphan Drug Designation, regulatory and gap analysis on going, clinical protocol complete</td>
</tr>
<tr>
<td>Gene Therapy for Hemophilia A</td>
<td>S. Croteau, A. Biffi</td>
<td>Spark Therapeutics</td>
<td>Site visit complete, IRB/IBC submission in progress</td>
</tr>
<tr>
<td>A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency</td>
<td>W.H. Tan</td>
<td>Dimension Therapeutics</td>
<td><strong>Active:</strong> SRC review stage, plan for early summer enrollment</td>
</tr>
<tr>
<td>SMA type I &amp; II (IV and IT)</td>
<td>B. Darras</td>
<td>AveXis</td>
<td><strong>Regulatory Stages:</strong> Protocols redesigned, GT SRC review stage, plan for early summer enrollment</td>
</tr>
<tr>
<td>CNL7 (Batten Disease) – AAV</td>
<td>A. Biffi</td>
<td>PI Initiated</td>
<td>Pre clinical development-18 mon to open</td>
</tr>
</tbody>
</table>
Founding Institutions:
Boston Children’s Hospital, Medical University, Hannover (MHH) (Germany)
International academic collaborations are driving new medicines in cell and gene therapy.
Among rare central nervous system diseases, Dravet Syndrome is a catastrophic epilepsy

- Dravet Syndrome is a rare pediatric epilepsy syndrome encompassing a range of cognitive/developmental delays, drug resistant seizures, and high mortality rates.

- A monogenic disease caused in 75% of cases by haploinsufficiency of the SCN1a gene that encodes a voltage-gated sodium channel.

- Incidence of Dravet: 1:15,000 to 1:20,000 (7,500 – 15,000 cases in the US) (Jenna Krueger et al, 2016)

- Current therapies only attempt to reduce seizures instead of targeting the root cause of the disease.
Tevard Bio is a for-profit company developing novel therapeutics for Dravet by targeting its underlying genetic cause

- Founded together with two businessmen who are fathers of daughters with Dravet Syndrome.

- Goal is to identify and develop approaches that could potentially lead to permanently or semi-permanently increasing levels of SCN1a by either:
  - Increasing the expression of the healthy SCN1a allele; or
  - Fixing/replacing the mutated copy of SCN1a

- Partnering with leaders to develop effective gene therapy approaches and delivery methods to the brain

  Our long term goal is to build a platform to deliver gene therapies for other monogenic CNS disorders
The basics of starting a biotech company

- Entrepreneurial faculty and a collaborative entrepreneurial environment.
- A top Scientific Advisory Board and Board of Directors
- Experienced biopharmaceutical leaders and workers
- Proprietary and protected intellectual property
- A solid business plan
- Solid financial backing, usually by venture capital
- Supportive infrastructure including a helpful government and regulatory environment
Policies of most U.S. research universities encourage faculty members to become entrepreneurs

• One day per week “Outside Professional Activity”
  – For-profit companies
  – Not-for-profit organizations

• Faculty can consult for and own stock in companies but cannot be an operating officer

• Clear conflict of interest rules
Entrepreneurial faculty generate a collaborative entrepreneurial environment.

- MIT has a culture of faculty entrepreneurs
  - Experienced serial entrepreneurs
  - Mentors of younger faculty
- MIT offers many entrepreneurship courses for faculty and students
  - Finance
  - Marketing
  - Intellectual property
  - Human resources
Geography is important: MIT and the Whitehead and Broad Institutes form the center of an ecosystem of biotech, pharmaceutical, and venture capital firms.
A top Board of Directors and Scientific Advisory Board

- Top retired or semi-retired executives with pharmaceutical or related business experience
- Top academic scientists, ideally with some business experience
- Given founder’s stock in the company
- Collegial and interactive - works well as a team
- Key to recruiting venture capital and other financial backing
- Interview and hire key company personnel
- Enables the company to be nimble and flexible and respond quickly to new opportunities and directions.
Experienced biopharmaceutical leaders and workers

- Top faculty entrepreneurs as founders or advisors
- Individuals with leadership experience in the biotech and pharmaceutical industries
- Highly trained and motivated Ph.D.-level researchers
- Trained technicians and lower level employees
- Experts in business, finance, law, government regulations
Proprietary and protected intellectual property

• Often but not necessarily developed in laboratories of the founding scientists

• Requires an excellent Technology Licensing Office
  – Patent protection
  – Licensing and royalty arrangements
  – Identifying corporate partners

• Requires outside legal advice
A solid business plan

- Cost of research, development, clinical testing over several years
- Target markets and market size
- Pricing
- Competition
- Patent protection and freedom to operate
- Collaborations with large or medium-sized companies
- Exit strategy – sell the company or have a public stock offering
Supportive infrastructure

• A helpful government and regulatory environment
• Accessible venture capital, angel investors, other funding sources
• Incubator laboratories
• Commercial laboratory space
Incubator laboratories support the growth of new life sciences companies across Massachusetts

- Tufts University Biotechnology Transfer Center
- UMass Dartmouth Advanced Technology & Manufacturing Center
- Cummings Properties
- Tufts University
- MIT\n- Cambridge Innovation Center
- Cambridge Biolabs
- BioSquare
- Creagen Biosciences Inc.
- Cape Ann Business Incubator
- Lab Central
- Massachusetts Biomedical Initiatives
- UMass Boston
- North Shore Life Sciences Accelerator
- Trade Center Executive Suites
- Launch
Lab Central – a Model Incubator for Start-up Biotechnology Companies: Shared Open Lab Space
Lab Central – a Model Incubator for Start-up Biotechnology Companies: Private Laboratories for ~10 Researchers
The basics of starting a biotech company

• Entrepreneurial faculty and a collaborative entrepreneurial environment.
• A top Scientific Advisory Board and Board of Directors
• Experienced biopharmaceutical leaders and workers
• Proprietary and protected intellectual property
• A solid business plan
• Solid financial backing, usually by venture capital
• Supportive infrastructure including a helpful government and regulatory environment
New types of therapeutics are entering clinical practice and form the basis of successful companies

- Small molecule drugs
- Proteins as therapeutics (~1980)
  - Monoclonal antibodies
  - Recombinant therapeutic proteins
- Cell therapies (~2010)
  - Replacement cells (e.g. pancreatic islets)
  - Engineered cells (e.g. red blood cells expressing new proteins; anti-cancer T cells)
- Nucleic acid therapies (~2010)
- Gene therapies (~2010)
- Gene editing (~2020?)